Program
PRMT5 Inhibitor TNG456
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Tango Therapeutics.
Furthest: phase 2, since Jan 24, 20251 company-led study, 1 open or runningNext primary completion: Mar 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tango Therapeutics | 11 open or running | phase 2since Jan 24, 2025 | Jan 24, 2025 | Mar 31, 2027phase 2 · NCT06810544 |
Also a collaborator on its studies: Eli Lilly.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 24, 2025First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06810544 · 191 planned · United States
Ahead
- Mar 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06810544
TargetBeta
PRMT5 →read by rule
“An orally bioavailable, blood-brain-barrier (BBB) penetrant and methylthioadenosine (MTA)-selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), ”NCIt, by rule
Other programs on PRMT5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| navlimetostat | Bristol-Myers Squibb | phase 3 | 10 |
| PRMT5 Inhibitor AZD3470 | AstraZeneca | phase 2 | 2 |
| JBI-778rule | jubilant-therapeutics-india-limited | phase 2 | 2 |
| PRMT5 Inhibitor BAY 3713372rule | Bayer | phase 2 | 1 |
| onametostatrule | Johnson & Johnson | phase 1 | 2 |
| PRMT5 Inhibitor SH3765rule | Nanjing Sanhome Pharmaceutical | phase 1 | 2 |
| PRMT5 Inhibitor BGB-58067rule | BeOne Medicines | phase 1 | 2 |
| PRMT5 Inhibitor IDE892rule | ideaya-biosciences | phase 1 | 1 |
| PEP08rule | pharmaengine | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06810544Carcinoma, Non-Small-Cell Lung · United States | 2 | Recruiting | Mar 31, 2027 | 191 |
How it is read
Names in the registry
- “TNG456”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.